Hosted on MSN51m
Boehringer Ingelheim announces Phase III schizophrenia failuresThe company has said that all three of its CONNEX trials failed to meet expectations showing no significant impact on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback